MBA CMA - SAB Biotherapeutics Ex CFO

SAB Biotherapeutics Management Efficiency

The company has return on total asset (ROA) of (0.4828) % which means that it has lost $0.4828 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9235) %, meaning that it created substantial loss on money invested by shareholders. SAB Biotherapeutics' management efficiency ratios could be used to measure how well SAB Biotherapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to gain to -0.73 in 2025. Return On Capital Employed is likely to gain to -1.13 in 2025. At this time, SAB Biotherapeutics' Total Assets are comparatively stable compared to the past year. Non Current Assets Total is likely to gain to about 24.9 M in 2025, whereas Other Current Assets are likely to drop slightly above 2.8 M in 2025.

Similar Executives

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. The company was founded in 2014 and is based in Sioux Falls, South Dakota. Sab Biotherapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 1 people. SAB Biotherapeutics (SABS) is traded on NASDAQ Exchange in USA. It is located in 777 W 41st St., Miami Beach, FL, United States, 33140 and employs 63 people. SAB Biotherapeutics is listed under Biotechnology category by Fama And French industry classification.

Management Performance

SAB Biotherapeutics Leadership Team

SAB Stock Performance Indicators

Additional Tools for SAB Stock Analysis